List of Excipients in Branded Drug FOSFOMYCIN TROMETHAMINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Zambon USA Ltd	FOSFOMYCIN TROMETHAMINE	fosfomycin tromethamine	82036-4274	ORANGE
Zambon USA Ltd	FOSFOMYCIN TROMETHAMINE	fosfomycin tromethamine	82036-4274	SACCHARIN
Zambon USA Ltd	FOSFOMYCIN TROMETHAMINE	fosfomycin tromethamine	82036-4274	SUCROSE
Zambon USA Ltd	FOSFOMYCIN TROMETHAMINE	fosfomycin tromethamine	82036-4274	TANGERINE

Generic Drugs Containing FOSFOMYCIN TROMETHAMINE

Company	Ingredient	NDC	Excipient
A-S Medication Solutions	granules for oral	50090-5826	ORANGE
A-S Medication Solutions	granules for oral	50090-5826	SACCHARIN
A-S Medication Solutions	granules for oral	50090-5826	SUCROSE
A-S Medication Solutions	granules for oral	50090-5826	TANGERINE
A-S Medication Solutions	fosfomycin tromethamine	50090-6130	ORANGE
A-S Medication Solutions	fosfomycin tromethamine	50090-6130	SACCHARIN
A-S Medication Solutions	fosfomycin tromethamine	50090-6130	SUCROSE

What are the Most Frequently-Used Excipients in FOSFOMYCIN TROMETHAMINE?

# Of NDCs	Excipient
1	.ALPHA.-TOCOPHEROL, DL-
1	ACACIA
2	MALTODEXTRIN
9	ORANGE
9	SACCHARIN
1	SACCHARIN SODIUM
1	SILICON DIOXIDE

Fosfomycin Tromethamine Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

Fosfomycin tromethamine is an off-patent oral antibacterial with a simple but commercially important formulation profile. The principal opportunity is not a new active ingredient patent. It is differentiation through palatability, reconstitution, dose presentation, stability, pediatric usability, hospital procurement, and reformulated delivery systems.

The reference U.S. product, Monurol, is a single-dose oral granule containing fosfomycin tromethamine equivalent to 3 g of fosfomycin. Its listed inactive ingredients are sucrose, saccharin, and orange flavor [1]. This relatively narrow excipient platform leaves room for products that address taste, sugar load, dosing convenience, administration volume, and special-population use.

What is the current FDA status of fosfomycin tromethamine?

Fosfomycin tromethamine is FDA-approved as an oral single-dose treatment for acute uncomplicated cystitis in women caused by susceptible strains of Escherichia coli and Enterococcus faecalis [1].

The approved product is supplied as a sachet of granules that is dissolved in water before oral administration. Fosfomycin tromethamine is not approved in the U.S. oral product label for pyelonephritis or complicated urinary tract infection. Its pharmacokinetic profile produces high urinary concentrations, but oral exposure is not a substitute for systemic therapy in upper-tract or bloodstream infections.

Regulatory attribute	U.S. reference product
Active ingredient	Fosfomycin tromethamine
Fosfomycin equivalent	3 g per sachet
Dosage form	Oral granules for solution
Administration	Single oral dose dissolved in water
FDA indication	Acute uncomplicated cystitis in women
Reference brand	Monurol
NDA	050717
Core exclusivity position	Mature, off-patent product with generic competition
Primary commercial constraint	Taste and administration experience

The FDA label instructs patients to dissolve the entire packet in water and not use hot water [1]. The formulation therefore has to balance rapid wetting, dispersion, palatability, chemical stability, and consistent delivery of the full dose.

What excipients are used in the reference fosfomycin tromethamine product?

The U.S. Monurol formulation contains sucrose, saccharin, and orange flavor [1].

Sucrose

Sucrose provides bulk and contributes to sweetness and mouthfeel. It also supports powder handling because the 3 g fosfomycin-equivalent dose requires a larger total sachet mass after conversion to the tromethamine salt and addition of excipients.

The main commercial limitations are:

• High sugar content relative to low-sugar or sugar-free alternatives
• Suitability concerns for diabetic or carbohydrate-restricted patients
• Potential dental-health concerns with repeated use, although the approved regimen is single dose
• Hygroscopicity and powder-flow considerations
• Potential incompatibility with certain moisture-sensitive manufacturing conditions

A sucrose-free product could be positioned for institutional formularies, diabetes-conscious prescribing, and markets where sugar declaration affects procurement or labeling.

Saccharin

Saccharin provides high-intensity sweetness at low concentration. It reduces the mass burden that would result from using a larger quantity of sucrose or another bulk sweetener.

Its commercial limitations are taste quality and regulatory-market acceptability. Saccharin can produce a lingering or metallic aftertaste, particularly when paired with strongly acidic, salty, or medicinal-tasting active ingredients.

Orange flavor

Orange flavor is intended to mask the unpleasant taste of fosfomycin and the salt character of fosfomycin tromethamine. Flavor performance is central because the product is dissolved in water and consumed as a relatively concentrated single dose.

Potential issues include:

• Variation in flavor perception across patient populations
• Stability of volatile flavor components
• Interaction with sweeteners and buffering agents
• Consumer preference for citrus, berry, neutral, or unflavored presentations
• Regulatory requirements for natural, artificial, allergen, and flavor-component declarations

A new product does not need to copy the orange profile. A multi-flavor product family, taste-masked neutral formulation, or better-performing citrus system could provide commercial differentiation.

What excipient strategy is best for a new fosfomycin tromethamine product?

The strongest strategy is a low-moisture, rapid-dispersing granule with improved taste and reduced sugar content.

Recommended target product profile

Attribute	Commercial target
Dose	3 g fosfomycin equivalent
Administration	One sachet dissolved in a small volume of water
Reconstitution	Rapid dispersion without vigorous shaking
Taste	Reduced salt, sulfurous, and medicinal notes
Sweetener	Sugar-free or reduced-sugar option
Flavor	Citrus or berry system with improved aftertaste control
Packaging	High-barrier unit-dose sachet
Stability	Robustness against moisture and flavor loss
Manufacturing	Standard wet or dry granulation with scalable filling
Regulatory route	ANDA for equivalent product; 505(b)(2) for differentiated clinical or delivery claims

The formulation should avoid unnecessary complexity. Every additional excipient increases the risk of altered dissolution, new impurities, stability failures, labeling requirements, or bioequivalence questions.

Which excipients can improve fosfomycin tromethamine palatability?

Taste masking should use a layered system rather than relying on a single sweetener.

Sweeteners

Potential candidates include:

• Sucralose
• Aspartame, where phenylalanine labeling is acceptable
• Acesulfame potassium
• Steviol glycosides
• Saccharin
• Reduced levels of sucrose or other polyols

Polyols such as mannitol, sorbitol, and xylitol can provide bulk and cooling effects. Their use is limited by gastrointestinal tolerance, hygroscopicity, and potential labeling requirements.

Flavor systems

Potential flavors include:

• Orange or mandarin
• Lemon-lime
• Berry
• Tropical fruit
• Neutral flavor with stronger taste masking

Flavor selection should be tested in the final reconstituted product rather than in the dry powder alone. Fosfomycin tromethamine’s taste profile changes substantially after dissolution, and the concentrated solution may expose bitterness or saltiness that is not apparent in the powder.

Taste-masking technologies

Commercially relevant options include:

• Ion-exchange resin complexes
• Polymer coating of active particles
• Lipid-based coating
• Cyclodextrin complexes
• Microencapsulation
• Flavor modulation using acidulants and cooling agents

These approaches create formulation and regulatory complexity. A coated or complexed active may change dissolution and absorption. For an ANDA, the most defensible approach is generally a composition that preserves rapid release and demonstrates comparable exposure without introducing a clinically meaningful food or administration effect.

What formulation patents could protect a fosfomycin tromethamine product?

The active ingredient and basic single-dose sachet concept offer limited exclusivity value. A commercially useful patent position would need to focus on a specific formulation or delivery problem.

Potential claim categories include:

1. A sugar-free or low-sugar granule composition with specified sweetener ratios.
2. A defined flavor and acidulant system that reduces bitterness or saltiness.
3. A moisture-controlled granule with improved stability.
4. A coated fosfomycin tromethamine particle that preserves rapid dissolution.
5. A unit-dose sachet with a defined reconstitution time and administration volume.
6. A pediatric dosage presentation with unit-dose strengths below 3 g.
7. A dual-compartment package separating moisture-sensitive flavor from the active granule.
8. A ready-to-drink liquid or concentrated liquid formulation.
9. A controlled-release or urinary-targeted formulation.
10. A combination product with a urinary analgesic or diagnostic component, subject to regulatory and clinical requirements.

A formulation patent is stronger when it links composition to measurable performance, such as dissolution time, impurity control, stability, taste-panel outcomes, or reduced administration volume. Broad claims covering routine sweeteners or flavorants are vulnerable to obviousness challenges.

When does fosfomycin tromethamine lose exclusivity?

The core oral fosfomycin tromethamine product is already commercially mature and generic competition exists. The principal U.S. market barrier is therefore regulatory execution, manufacturing reliability, and contracting rather than remaining basic-drug exclusivity.

The Orange Book remains the operative source for current U.S. patent listings, regulatory exclusivity, therapeutic equivalence codes, and reference-product information [2]. A new sponsor should assess the live Orange Book record and FDA approval history before relying on any patent or exclusivity assumption.

Exclusivity element	Commercial assessment
Basic active ingredient	Mature and off-patent
Original oral granule concept	Mature technology
Reference product	Established U.S. approval
Generic entry	Already present
New formulation	Potentially protectable if technically differentiated
New indication	Potential 505(b)(2) or supplemental pathway opportunity
Pediatric product	Possible market niche, but clinical and dosing support may be required
New delivery system	Higher development cost and greater regulatory risk

What generic entry risks exist for fosfomycin tromethamine?

Generic entry risk is high for a conventional oral granule that matches the reference product’s dosage form, strength, route, and administration instructions.

A conventional ANDA competitor can target:

• 3 g fosfomycin-equivalent strength
• Single-dose sachet packaging
• Water-reconstituted administration
• Similar granule particle-size distribution
• Similar dissolution and drug-release behavior
• Comparable sweetener and flavor performance

The principal barriers are not likely to be composition patents. They are commercial scale, product quality, and bioequivalence execution.

A sponsor pursuing an ANDA should control:

• Assay and content uniformity
• Moisture uptake
• Sachet seal integrity
• Granule segregation
• Reconstitution time
• Taste and odor consistency
• Fosfomycin-related impurities
• Stability after manufacture and during distribution
• Batch-to-batch flavor performance

A generic product with inferior taste may still obtain approval but lose market share in retail channels. Hospital and wholesaler purchasing may place greater weight on price, supply continuity, and contract terms.

Are Paragraph IV challenges relevant to fosfomycin tromethamine?

Paragraph IV risk is relevant only to any unexpired, Orange Book-listed patent associated with the reference product or a later-listed formulation. Because the basic product is mature, a Paragraph IV strategy would most likely target a formulation, use, packaging, or manufacturing patent rather than the active ingredient itself.

A Paragraph IV filing could create:

• A 30-month stay if statutory requirements are met
• Hatch-Waxman litigation
• At-risk launch exposure
• Settlement negotiations
• Potential first-filer or market-entry advantages, depending on the patent and approval record

For a reformulated fosfomycin product, the sponsor must separate two business cases:

1. A low-cost ANDA product with limited intellectual-property differentiation.
2. A formulation-led product supported by patents, clinical evidence, or a 505(b)(2) regulatory strategy.

The first case offers faster market access but weak pricing power. The second offers stronger differentiation but requires evidence that the formulation improves a clinically or commercially meaningful attribute.

What manufacturing and intellectual-property barriers affect fosfomycin tromethamine?

Manufacturing barriers are moderate. The dosage form is technically familiar, but the high unit dose and moisture-sensitive powder presentation require disciplined process controls.

Manufacturing considerations

Fosfomycin tromethamine products may use direct blending, dry granulation, wet granulation, or fluid-bed processing. The selected process must maintain dose uniformity and prevent excessive moisture exposure.

Key process variables include:

• Granule size distribution
• Bulk density
• Flowability
• Moisture content
• Drying endpoint
• Flavor retention
• Sachet fill accuracy
• Heat-seal performance
• Dissolution after storage

A wet-granulation process may improve granule strength but add moisture and drying requirements. Dry granulation reduces water exposure but may create segregation or poor compaction. Direct blending is simpler but may be less robust at high active loadings and with low-dose flavor or sweetener components.

Intellectual-property barriers

The strongest potential IP positions are likely to involve:

• Specific taste-masking compositions
• Moisture-barrier packaging
• Improved stability under defined humidity conditions
• Pediatric or geriatric administration formats
• Alternative liquid or dispersible dosage forms
• New dosing regimens supported by clinical data
• Combination therapy or adjunctive treatment

A patent that merely substitutes one conventional sweetener for another is unlikely to provide durable protection without demonstrated unexpected performance.

What commercial opportunities exist beyond the reference sachet?

Sugar-free retail product

A sugar-free version could target patients who prefer lower carbohydrate products and pharmacies seeking a differentiated generic. The commercial value would depend on taste acceptance and whether the product avoids gastrointestinal side effects associated with certain polyols.

Pediatric urinary-tract-infection product

Pediatric use is a potential niche, but the current U.S. reference indication is for acute uncomplicated cystitis in women [1]. A pediatric product would require appropriate dosing, safety support, and regulatory positioning. A lower-strength sachet could improve dosing flexibility, but it should not be marketed as an approved pediatric product without supporting authorization.

Hospital and long-term-care supply

Hospitals may value unit-dose packaging, rapid preparation, reliable supply, and reduced medication-preparation steps. A sachet with clearer instructions and lower reconstitution volume could support institutional adoption.

International markets

Fosfomycin tromethamine is used internationally in different regulatory and clinical contexts. European and other national products may have different excipient systems, packaging formats, and labeling requirements. Geographic expansion requires country-specific assessment of approved indications, antimicrobial stewardship rules, pediatric status, and generic substitution.

Reformulated liquid product

A ready-to-drink or concentrated liquid could improve convenience but would create substantial stability, preservative, packaging, and microbial-control requirements. This is a higher-cost opportunity than a dry sachet and may require a 505(b)(2) strategy if the product differs materially from the reference product.

Combination and adherence products

A product paired with a urinary pain-management component or an adherence-oriented administration system could create commercial differentiation. Combination products introduce additional clinical, regulatory, labeling, and safety obligations and are not low-risk extensions.

How does fosfomycin tromethamine compare with competing oral urinary antibiotics?

Fosfomycin’s commercial position is defined by single-dose administration and activity against selected resistant urinary pathogens. It competes with multi-day oral therapies such as nitrofurantoin, trimethoprim-sulfamethoxazole, and selected beta-lactams.

Attribute	Fosfomycin tromethamine	Nitrofurantoin	Trimethoprim-sulfamethoxazole
Typical uncomplicated-cystitis regimen	Single dose	Multiple doses over several days	Multi-day course
Key commercial advantage	Convenience and urinary exposure	Established efficacy and low cost	Familiarity and broad use
Main formulation issue	Taste and reconstitution	Capsule or tablet swallowing	Tablet or suspension tolerability
Resistance positioning	Useful against selected resistant organisms	Resistance varies by region	Resistance can be substantial
Upper-tract use	Not appropriate under U.S. oral label	Limited by clinical context	Used selectively
Differentiation opportunity	Better taste, sugar-free, easier dosing	Adherence and tolerability	Suspension and pediatric dosing

Clinical guidelines place fosfomycin among options for uncomplicated cystitis but do not treat it as a universal substitute for other urinary antibiotics [3]. Product positioning must remain consistent with approved indications and antimicrobial-stewardship requirements.

What licensing deals could create value for fosfomycin tromethamine?

Licensing value is more likely to arise from technology than from the active ingredient. Potential deal structures include:

• Licensing a taste-masking platform for an ANDA product
• Regional rights for a reformulated sachet
• Contract development and manufacturing agreements
• Co-development of pediatric dosage strengths
• Licensing a moisture-barrier packaging system
• Supply agreements with hospital distributors
• Rights to a 505(b)(2) liquid or modified-release formulation

A conventional generic license is unlikely to command substantial upfront value unless it includes manufacturing capacity, regulatory approvals, an established distribution network, or preferential access to a major market.

What is the revenue exposure and competitive outlook?

Revenue exposure for the reference product is vulnerable to generic price erosion because the active ingredient and core dosage form are mature. A differentiated product can protect margin only if it solves a recognized problem and obtains defensible channel access.

Product strategy	Price power	Development risk	IP potential	Commercial outlook
Conventional 3 g sachet	Low	Low to moderate	Low	Volume-driven generic
Sugar-free sachet	Moderate	Moderate	Moderate	Retail and institutional niche
Superior taste-masked sachet	Moderate	Moderate	Moderate	Patient-preference differentiation
Pediatric lower-strength sachets	Moderate	Moderate to high	Moderate	Specialty and international opportunity
Ready-to-drink liquid	Higher	High	Moderate to high	Convenience-led reformulation
Modified-release or targeted delivery	Potentially high	High	High	Long-cycle, uncertain return
Combination product	Variable	High	Variable	Requires strong clinical rationale

The most credible near-term opportunity is a differentiated dry granule that retains the reference product’s single-dose convenience while improving taste, reducing sugar, and simplifying reconstitution.

How strong is the patent estate for fosfomycin tromethamine?

The core patent estate is weak from a lifecycle-management perspective because the product is established and generic competition exists. A new sponsor should not assume that a conventional excipient substitution will create durable exclusivity.

Patent strength improves when the sponsor can demonstrate:

• A non-obvious excipient combination
• Superior taste outcomes in validated human or sensory testing
• Improved stability under accelerated conditions
• Reduced reconstitution time
• Lower administration volume
• Improved adherence or completion rates
• A clinically supported new population or indication
• Manufacturing advantages that are difficult to design around

Trade-secret protection may be important for flavor ratios, granulation parameters, coating processes, and packaging specifications even where patent protection is narrow.

Key Takeaways

• Fosfomycin tromethamine is a mature, off-patent oral antibiotic with generic competition.
• The U.S. reference product uses sucrose, saccharin, and orange flavor in a 3 g single-dose sachet.
• The strongest near-term opportunity is a sugar-free or reduced-sugar, taste-masked granule with rapid reconstitution.
• Formulation patents should claim measurable performance, not routine excipient substitution.
• A conventional ANDA offers lower development risk but limited pricing power.
• A 505(b)(2) strategy may support a liquid, pediatric, modified-release, or otherwise differentiated product, but it carries higher regulatory and clinical costs.
• Manufacturing execution, moisture control, flavor stability, and sachet integrity are central commercial risks.
• The most attractive licensing targets are formulation, packaging, manufacturing, and regional commercialization technologies.
• Fosfomycin should be positioned for approved uncomplicated cystitis use and selected resistance scenarios, not as a general systemic urinary-tract antibiotic.

Frequently Asked Questions

Can fosfomycin tromethamine be formulated without sucrose?

Yes. Sucrose can potentially be replaced with polyols, soluble fillers, or combinations of high-intensity sweeteners and bulking agents. The replacement must preserve powder flow, reconstitution, taste, stability, and bioequivalence.

Is fosfomycin tromethamine suitable for a liquid antibiotic product?

It can be evaluated in a liquid or concentrated liquid formulation, but the product would face greater stability, microbial-control, preservative, packaging, and regulatory requirements than a dry sachet.

What is the best excipient for masking fosfomycin taste?

No single excipient is universally optimal. A combined system using a high-intensity sweetener, flavor, acidulant or buffer, and possibly particle coating is more likely to improve the final reconstituted taste than one sweetener alone.

Can a new flavor support patent protection for fosfomycin tromethamine?

A flavor alone generally offers limited protection. A stronger patent position would connect the flavor system to a defined composition, unexpected taste improvement, stability result, or reconstitution performance.

Does a sugar-free fosfomycin product automatically qualify for a new FDA approval pathway?

No. The regulatory pathway depends on the extent of formulation and labeling differences from the reference product. A conventional equivalent may fit an ANDA, while a materially different product may require a 505(b)(2) application or other regulatory strategy.

References

1. U.S. Food and Drug Administration. (2023). Monurol (fosfomycin tromethamine) oral granules prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. Infectious Diseases Society of America. (2011). Clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women. Clinical Infectious Diseases, 52(5), e103-e120.